Navigating the Choice of NOACs for Stroke Prevention in AF

Navigating the Choice of NOACs for Stroke Prevention in AF

CardiologyFamily MedicineGeneral PracticeInternal MedicineNeurology
A badge with ribbon in color black Cat3B: 1 Point | An analog clock in color black 1 Hour | A black calendar with white triangle in center that has a black exclamation point in the middle 05 Aug 2022 

Overview

About this course

In patients with atrial fibrillation (AF), stroke prevention remains as one of the cornerstones of management. This is accomplished using either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants (NOACs). The use of NOACs has led to improved clinical outcomes in AF patients in terms of stroke prevention. This e-learning module summarizes important information health care practitioners can use and advise their patients about NOACs, including data on their efficacy and safety, their guidelines-based indications, and reversal agents available in case of NOAC-induced bleeding.


Learning outcomes

Upon completion of the educational activity, health care providers should be able to:
  • Understand the importance of stroke prevention in patients with AF
  • Learn the difference between Vitamin K antagonists and NOACS
  • Identify the 4 approved NOACs and their uses based on clinical guidelines
  • Learn about reversal agents available in case of NOAC-induced bleeding

Topics covered

  • Introduction (stroke prevention in AF, stroke risk stratification, Vitamin K antagonists versus NOACs)
  • Studies and trials on the 4 approved NOACs
  • NOACs in the guidelines
  • Different types of reversal agents
  • Patient specific indications for using each NOAC
  • Acceptability, accessibility, and affordability of NOACs

1 CME Point Available

A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.

Participant's registration is independently sponsored by:

Pfizer_Logo_Color_RGB.png